Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
56.26
-0.07 (-0.12%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Sanofi-Aventis S.A. ADR
< Previous
1
2
3
4
5
6
7
8
9
...
27
28
Next >
Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates
August 26, 2024
State and local governments suing PBMs and drug companies over insulin prices have long benefited from the same rebate system they now criticize, leaving patients burdened by high costs and limited...
Via
Benzinga
Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy?
August 24, 2024
Don't be too quick to jump on the Wall Street bandwagon.
Via
The Motley Fool
ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst
August 20, 2024
"FDA recently approved ARS Pharmaceuticals' neffy nasal spray for emergency allergic reactions, offering an alternative to epinephrine autoinjectors like EpiPen. Cantor sees strong market potential and...
Via
Benzinga
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
August 19, 2024
Its 12-month relative strength performance is impressive, but Novavax now faces resistance.
Via
Investor's Business Daily
NASDAQ:SNY is probably undervalued for the fundamentals it is displaying.
August 19, 2024
SANOFI-ADR (NASDAQ:SNY) appears to be flying under the radar despite its strong fundamentals.
Via
Chartmill
NASDAQ:SNY may be ready to breakout.
August 12, 2024
Will SANOFI-ADR breakout?
Via
Chartmill
Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk
August 16, 2024
A Florida State Court sided with GSK, dismissing expert testimonies that linked ranitidine to prostate cancer, reflecting a broader scientific consensus that there is no consistent evidence supporting...
Via
Benzinga
3 Biotech Stocks to Buy on the Dip: August 2024
August 15, 2024
These are three of the best biotech stocks to buy on the dip due to their strong fundamentals and market positioning.
Via
InvestorPlace
AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering
August 14, 2024
The company is working on treatments for immunological diseases, including eczema and rheumatoid arthritis.
Via
Investor's Business Daily
FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment
August 09, 2024
FDA approves ARS Pharmaceuticals' Neffy, the first nasal spray for treating severe allergic reactions and anaphylaxis. This new option offers a non-injection alternative to epinephrine autoinjectors,...
Via
Benzinga
Exposures
Product Safety
COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit
August 08, 2024
Novavax reported Q2 2024 revenue of $415 million, missing estimates, with net income rising to $162 million. EPS increased to $0.99, below expectations. The company revised its 2024 revenue guidance to...
Via
Benzinga
Exposures
COVID-19
Sanofi's Approved Blood Cancer Drug Sarclisa Shows Improved Progression-Free Survival In Patients Eligible For Transplant
August 08, 2024
Sanofi's phase 3 GMMG-HD7 study reveals that Sarclisa, combined with lenalidomide, bortezomib, and dexamethasone, significantly prolongs progression-free survival in newly diagnosed multiple myeloma...
Via
Benzinga
Where Will Novavax Be in 5 Years?
August 03, 2024
Its been a good year so far for the biotech, but how long can it keep the momentum going?
Via
The Motley Fool
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
August 01, 2024
Regeneron Pharmaceuticals Q2 results: adjusted EPS of $11.56 (up 13%), revenue of $3.55 billion (up 12%). Key drivers: Eylea HD, Dupixent, and Libtayo. Notable: 18% decline in Eylea US sales; 42%...
Via
Benzinga
JPMorgan Just Cut Its Price Target on These 3 Stocks: July 31, 2024
July 31, 2024
Analysts from JPMorgan Chase have expressed their concern about the outlook for these stocks with lowered price targets.
Via
InvestorPlace
JPMorgan Just Issued a Warning on Novavax (NVAX) Stock
July 30, 2024
Novavax has inked a key vaccine deal with Sanofi, but NVAX stock is down after JPMorgan warned about overvaluation concerns.
Via
InvestorPlace
Sanofi (SNY) Q2 2024 Earnings Call Transcript
July 25, 2024
SNY earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
July 25, 2024
Wall Street strongly rebounded Thursday after Wednesday’s slump, driven by stronger-than-expected economic growth in the last quarter, countering concerns of a slowdown.
Via
Benzinga
Topics
Economy
Exposures
Economy
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
July 25, 2024
Sanofi reports a 7.8% YoY sales increase in Q2, with sales reaching $11.57 billion, beating consensus. Key highlights include a 29.2% rise in Dupixent sales and a stable 2024 business EPS forecast.
Via
Benzinga
25 Best Artificial Intelligence Stocks to Buy Right Now
July 25, 2024
Artificial intelligence is revolutionizing industries across the board. These 25 companies span the spectrum, providing investors with a diversified basket of AI-centric equities.
Via
The Motley Fool
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Nasdaq, S&P Futures Slide On More Negative Tech Tidings As Focus Shifts To Q2 GDP Data: Strategist Says Trump Trades May Not Work Even If Ex-President Retakes White House
July 25, 2024
Sentiment continues to be jittery, with the major index futures priming for a lower opening on Thursday as traders look ahead to the first read of second-quarter GDP data and more earnings. The tech...
Via
Benzinga
Topics
Government
Stocks
Exposures
Political
US Equities
American Airlines, AstraZeneca And 3 Stocks To Watch Heading Into Thursday
July 25, 2024
Via
Benzinga
AstraZeneca, Sanofi And Other Pharma Giants Pursue Chinese Deals Despite Rising US-China Strife
July 23, 2024
The aim is to strengthen their drug pipelines and expand their presence in the world's second-largest pharmaceutical market.
Via
Benzinga
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
July 17, 2024
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed.
Via
Benzinga
Exposures
COVID-19
Stable Blue-Chip Stocks to Buy Before Earnings Season
July 17, 2024
Don't miss out on these stable blue-chip stocks to buy now. Explore their potential for steady returns and long-term portfolio growth.
Via
InvestorPlace
Senate To Review Novo Nordisk's Levemir Insulin Discontinuation
July 16, 2024
Novo Nordisk will meet with U.S. Senate aides to discuss the discontinuation of Levemir, its long-acting insulin, amid concerns about manufacturing constraints and patient access. Senators press for...
Via
Benzinga
Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally
July 21, 2024
The earnings parade continues this week with a slightly accelerated tempo as analysts brace for a healthy reporting season.
Via
Benzinga
Sanofi's $20B Consumer Health Unit Sale: Goldman Sachs, Morgan Stanley Line Up $6.5B Financing
July 12, 2024
Explore the €6 billion financing effort by banks for Sanofi's consumer health division sale. Discover the latest in high-stakes pharmaceutical industry deals.
Via
Benzinga
Bernie Sanders Targets High Prices of Ozempic and Wegovy In US
July 11, 2024
Senator Bernie Sanders is pushing Novo Nordisk to lower U.S. prices for weight-loss drugs Ozempic and Wegovy, as part of a broader effort to reduce drug costs and expand Medicare price negotiations.
Via
Benzinga
EXCLUSIVE: VeeCon 2024 Announces Danica Patrick, Jerome Bettis, Paul Scheer, Mike Posner, Liquid Death CEO Mike Cessario As New Speakers
July 11, 2024
VeeCon will bring the best of business, pop culture and Web3 in a multi-day conference hosted by serial entrepreneur and VeeFriends founder Gary Vaynerchuk (aka Gary Vee) for a
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
27
28
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.